EPH Receptor A5 anticorps (Extracellular, N-Term)

N° du produit ABIN7884938

Cet anticorps anti-EPH Receptor A5 Polyclonal Lapin (ABIN7884938) détecte spécifiquement EPH Receptor A5 dans WB et IHC. L’anticorps est réactif avec des échantillons de Humain, Souris et Rat.

Aperçu rapide pour EPH Receptor A5 anticorps (Extracellular, N-Term) (ABIN7884938)

Antigène: EPH Receptor A5 (EPHA5)

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EPH Receptor A5 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Classe de qualité: Carrier-free

Détail du produit anti-EPH Receptor A5 anticorps

Épitope: AA 357-369, Extracellular, N-Term

Fonction: A Rabbit Polyclonal Antibody to EphA5 (Extracellular)

Homologie: Rat,human - 12 out of 13 amino acids identical.

Purification: Affinity purified on immobilized antigen.

Immunogène: (C)KSKETSITAEGLK, corresponding to amino acid residues 357 - 369 of mouse EPHA5

Isotype: IgG

Information d'application

Indications d'application: The optimal concentration should be determined by the user

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: 0.2 mL double distilled water (DDW).

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Agent conservateur: Without preservative

Stock: -20 °C

Stockage commentaire: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Détails sur EPH Receptor A5

Antigène: EPH Receptor A5 (EPHA5)

Autre désignation: EPHA5

Sujet:

Synonyms: Ephrin type A receptor 5, Brain specific kinase, EPHA5

Description:

EphA5 (EPH Receptor A5) is a member of the Eph receptor tyrosine kinase family, which is the largest group of receptor tyrosine kinases (RTKs) in the human genome. They are divided into two classes-EphA and EphB-based on sequence similarity and ligand binding preferences. EphA receptors (EphA1-A10) typically bind to glycosylphosphatidylinositol (GPI)-anchored ephrin-A ligands, whereas EphB receptors (EphB1-B6) bind to transmembrane ephrin-B ligands.1

EphA5 is predominantly expressed in the developing central nervous system, especially in the cortex, hippocampus, olfactory bulb, and retina. It is critically involved in axon guidance, particularly in the formation of retinotectal and thalamocortical projections, contributing to the correct mapping of neural circuits. In the adult brain, EphA5 influences dendritic spine maturation and synaptic plasticity, which are fundamental for learning and memory.2,3

Eph receptors, including EphA5, are often dysregulated in cancer. EphA5 displays context-dependent roles in cancer, acting as either a tumor suppressor or, in some cases, a tumor promoter, depending on the cellular environment and tumor type. Its role is influenced by its expression pattern, epigenetic status, and interactions with other signaling pathways.4 In certain cancers such as breast and prostate, EphA5 is downregulated, suggesting a tumor-suppressive function, while in others like lung and gastric cancer, EphA5 expression is elevated and correlates with a more aggressive cancer.5,6

All these makes EphA5 a promising target for therapeutic intervention. Indeed, recently an antibody-drug conjugate (ADC) targeting EphA5, has been developed as a highly selective target for directed anticancer therapy.7

ID gène: 13839

UniProt: Q60629

Pathways: Signalisation RTK